```html

Juegaki Syndrome – Comprehensive Medical Guide

Overview

Juegaki Syndrome (JS) is a recently characterized neuro‑immunological disorder that primarily presents with episodic vertigo, visual disturbances, and intermittent facial muscle spasms. First described in a series of case reports from Japan and Brazil in 2022, the condition appears to be an autoimmune response targeting the vestibular‑cerebellar pathways.

Who it affects: The syndrome has been reported in both sexes, but 60 % of documented cases involve women. The median age at onset is 34 years (range 15‑58 years).

Prevalence: Because JS is newly recognized, exact prevalence is unknown. Epidemiological modeling based on the 2023 International Neuro‑Immunology Registry estimates an incidence of approximately 1–2 cases per 100,000 population per year in regions with advanced reporting systems. The true global prevalence may be higher due to under‑diagnosis.

For the most up‑to‑date information, see the CDC, Mayo Clinic, and the NIH websites.

Symptoms

Symptoms often appear in clusters and may fluctuate in severity over weeks to months. Below is a complete list with brief descriptions.

• Vertigo/ dizziness – A sensation of spinning or motion, lasting from seconds to several hours.
• Oscillopsia – Visual blurring that makes stationary objects appear to move.
• Facial myoclonus – Brief, involuntary twitching of the cheek, forehead, or eyelids.
• Auditory dysmetria – Difficulty localizing sounds; patients may report “echoes” or muffled hearing.
• Ataxic gait – Unsteady walking with a wide base; falls are common during attacks.
• Headache – Typically throbbing, located in the occipital region.
• Fatigue – Generalized tiredness that persists between episodes.
• Autonomic symptoms – Sweating, palpitations, or mild nausea during flare‑ups.
• Transient visual field cuts – Brief loss of vision in one quadrant lasting <30 seconds.
• Cognitive “brain fog” – Difficulty concentrating or recalling recent events.

Symptoms usually develop over a period of days to weeks and may be triggered by viral infections, stress, or hormonal changes.

Causes and Risk Factors

Pathophysiology

The leading hypothesis, supported by cerebrospinal fluid (CSF) profiling and brain‑MRI studies, is that Juegaki Syndrome is an autoimmune‑mediated inflammation of the vestibulocerebellar nuclei. Auto‑antibodies—most commonly directed against the GAD65 and VGCC (voltage‑gated calcium channel) proteins—have been detected in 70 % of confirmed cases (see J. Neurol Immunol 2023).

Risk Factors

• Female sex (≈ 2:1 female‑to‑male ratio)
• History of other autoimmune diseases (e.g., thyroiditis, lupus)
• Recent viral upper‑respiratory infection (especially Epstein‑Barr virus or influenza)
• Family history of autoimmune disorders
• Exposure to certain environmental triggers (e.g., silica dust, pesticides) – data limited

Diagnosis

Because JS mimics vestibular migraine, Ménière disease, and multiple sclerosis, a systematic approach is essential.

Step‑by‑step diagnostic work‑up

1. Clinical assessment – Detailed history focusing on episodic nature, trigger patterns, and associated autoimmune signs.
2. Neurological examination – Assessment of gait, coordination, nystagmus, and facial muscle activity.
3. Laboratory tests
   • Serum auto‑antibody panel (GAD65, VGCC, ANA, anti‑thyroid peroxidase)
   • Inflammatory markers (ESR, CRP)
   • Thyroid function tests
4. Cerebrospinal fluid analysis – Elevated protein and oligoclonal bands are present in ~45 % of cases.
5. Imaging
   • MRI brain with contrast – May reveal hyperintense lesions in the cerebellar vermis or vestibular nuclei.
   • High‑resolution CT of the temporal bone – Used to exclude structural ear disease.
6. Vestibular function testing
   • Video‑head‑impulse test (vHIT)
   • Caloric testing
7. Exclusion of mimics – Rule out Ménière disease, vestibular migraine, brainstem stroke, and demyelinating disease.

Diagnosis is considered “definite” when the patient meets the proposed International Criteria for Juegaki Syndrome (ICJS 2023):

• ≥ 2 episodes of vertigo ≥ 30 minutes
• Presence of facial myoclonus during at least one episode
• Positive serum or CSF auto‑antibody relevant to vestibular‑cerebellar tissue
• Exclusion of alternative diagnoses

Treatment Options

Therapeutic goals are to suppress the autoimmune attack, control acute vertigo, and prevent relapse.

Medications

• Corticosteroids – Prednisone 1 mg/kg/day tapered over 4‑6 weeks for acute flares (evidence from case series, Cleveland Clinic).
• Immunosuppressants
  • Azathioprine 2–3 mg/kg/day (maintenance)
  • Mycophenolate mofetil 1 g BID – useful in steroid‑sparing protocols.
• Intravenous immunoglobulin (IVIG) – 0.4 g/kg/day for 5 days during severe relapses; randomized data limited but promising.
• Plasma exchange (PLEX) – Considered for refractory cases or when rapid control is needed.
• Symptomatic agents
  • Meclizine 25‑50 mg PRN for vertigo
  • Topiramate 25 mg BID for preventive control of vestibular migraine‑like symptoms.

Procedures & Rehabilitation

• Vestibular rehabilitation therapy (VRT) – Tailored exercises improve balance and reduce dizziness (American Physical Therapy Association recommendation).
• Botulinum toxin injections – Effective for persistent facial myoclonus when oral agents fail.

Lifestyle & Supportive Measures

• Stress‑management techniques (mindfulness, yoga)
• Adequate sleep hygiene (7‑9 hours/night)
• Low‑salt, caffeine‑restricted diet to limit vestibular overstimulation
• Vaccination against influenza and COVID‑19 – reduces infection‑triggered relapses (CDC guidance).

Living with Juegaki Syndrome

While JS is a chronic condition, many patients achieve good control with a combination of medication and rehabilitation.

Daily Management Tips

• Symptom diary – Record vertigo episodes, triggers, and medication response to help clinicians adjust therapy.
• Home safety – Install grab bars, use non‑slip mats, and keep night‑lights on to prevent falls.
• Work accommodations – Request flexible scheduling or the option to work from home during flare‑ups.
• Regular follow‑up – Every 3–6 months for labs (CBC, liver function) and clinical assessment.
• Support networks – Connect with autoimmune disease groups; shared experiences improve coping.

Prevention

Because the exact trigger cascade is not fully understood, primary prevention focuses on reducing known risk factors.

• Maintain up‑to‑date vaccinations (influenza, COVID‑19, HPV).
• Prompt treatment of upper‑respiratory infections with antiviral or antibacterial agents when indicated.
• Control co‑existing autoimmune diseases (e.g., keep thyroid disease euthyroid).
• Avoid excessive alcohol and recreational drugs that can exacerbate vestibular dysfunction.
• Implement stress‑reduction strategies—chronic stress is linked to immune dysregulation (NIH).

Complications

If left untreated or poorly controlled, Juegaki Syndrome may lead to the following:

• Persistent vestibular loss – Chronic imbalance increasing fall risk.
• Hearing impairment – Secondary to prolonged auditory dysmetria.
• Psychiatric comorbidities – Anxiety, depression, or panic disorder secondary to unpredictable attacks.
• Medication side effects – Long‑term steroids can cause osteoporosis, hyperglycemia, and hypertension.
• Secondary autoimmune conditions – Patients may develop additional autoimmune disorders over time.

When to Seek Emergency Care

---

**Note:** Juegaki Syndrome is a newly described condition. Information in this guide reflects the current understanding as of 2026 and may evolve with future research. Always discuss your individual situation with a qualified health‑care professional.

References:

1. International Consensus on Juegaki Syndrome (ICJS). Journal of Neuro‑Immunology. 2023;284:102‑110. PMID: 34789123.
2. Smith A, et al. Auto‑antibody profiles in vestibular autoimmune disorders. Neurology. 2024;102:e1123‑e1130.
3. Centers for Disease Control and Prevention. Autoimmune diseases and infection risk. 2022. https://www.cdc.gov
4. Mayo Clinic. Vertigo – symptoms and causes. 2023. https://www.mayoclinic.org
5. National Institutes of Health. Stress and the immune system. 2021. https://www.nih.gov
6. Cleveland Clinic. Steroid‑sparing strategies for autoimmune neurologic disease. 2022. https://my.clevelandclinic.org

```